One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin

Daniel B. Brown, Carin F. Gonsalves, Charles J. Yeo, Agnes K. Witkiewicz, Brian I. Carr

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.

Original languageEnglish
Pages (from-to)767-769
Number of pages3
JournalOncology Reports
Volume24
Issue number3
DOIs
Publication statusPublished - Sep 2010

Fingerprint

gemcitabine
Cisplatin
Survival
Liver
Adenocarcinoma
Neoplasm Metastasis
Therapeutics
Research
Neoplasms
Pancreatic Carcinoma

Keywords

  • Chemoembolization
  • Gemcitabine
  • Pancreatic carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin. / Brown, Daniel B.; Gonsalves, Carin F.; Yeo, Charles J.; Witkiewicz, Agnes K.; Carr, Brian I.

In: Oncology Reports, Vol. 24, No. 3, 09.2010, p. 767-769.

Research output: Contribution to journalArticle

Brown, Daniel B. ; Gonsalves, Carin F. ; Yeo, Charles J. ; Witkiewicz, Agnes K. ; Carr, Brian I. / One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin. In: Oncology Reports. 2010 ; Vol. 24, No. 3. pp. 767-769.
@article{50c44867c9ce40ecbedc9d9087f4c0b0,
title = "One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin",
abstract = "While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.",
keywords = "Chemoembolization, Gemcitabine, Pancreatic carcinoma",
author = "Brown, {Daniel B.} and Gonsalves, {Carin F.} and Yeo, {Charles J.} and Witkiewicz, {Agnes K.} and Carr, {Brian I.}",
year = "2010",
month = "9",
doi = "10.3892/or-00000919",
language = "English",
volume = "24",
pages = "767--769",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin

AU - Brown, Daniel B.

AU - Gonsalves, Carin F.

AU - Yeo, Charles J.

AU - Witkiewicz, Agnes K.

AU - Carr, Brian I.

PY - 2010/9

Y1 - 2010/9

N2 - While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.

AB - While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.

KW - Chemoembolization

KW - Gemcitabine

KW - Pancreatic carcinoma

UR - http://www.scopus.com/inward/record.url?scp=77956325761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956325761&partnerID=8YFLogxK

U2 - 10.3892/or-00000919

DO - 10.3892/or-00000919

M3 - Article

C2 - 20664985

AN - SCOPUS:77956325761

VL - 24

SP - 767

EP - 769

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 3

ER -